362 related articles for article (PubMed ID: 25751105)
1. Role of Activin A and myostatin in human cancer cachexia.
Loumaye A; de Barsy M; Nachit M; Lause P; Frateur L; van Maanen A; Trefois P; Gruson D; Thissen JP
J Clin Endocrinol Metab; 2015 May; 100(5):2030-8. PubMed ID: 25751105
[TBL] [Abstract][Full Text] [Related]
2. [Role of Activin A and Myostatin in cancer cachexia].
Thissen JP; Loumaye A
Ann Endocrinol (Paris); 2013 May; 74(2):79-81. PubMed ID: 23566617
[TBL] [Abstract][Full Text] [Related]
3. Circulating Activin A predicts survival in cancer patients.
Loumaye A; de Barsy M; Nachit M; Lause P; van Maanen A; Trefois P; Gruson D; Thissen JP
J Cachexia Sarcopenia Muscle; 2017 Oct; 8(5):768-777. PubMed ID: 28712119
[TBL] [Abstract][Full Text] [Related]
4. Myokines in treatment-naïve patients with cancer-associated cachexia.
de Castro GS; Correia-Lima J; Simoes E; Orsso CE; Xiao J; Gama LR; Gomes SP; Gonçalves DC; Costa RGF; Radloff K; Lenz U; Taranko AE; Bin FC; Formiga FB; de Godoy LGL; de Souza RP; Nucci LHA; Feitoza M; de Castro CC; Tokeshi F; Alcantara PSM; Otoch JP; Ramos AF; Laviano A; Coletti D; Mazurak VC; Prado CM; Seelaender M
Clin Nutr; 2021 Apr; 40(4):2443-2455. PubMed ID: 33190987
[TBL] [Abstract][Full Text] [Related]
5. Low testosterone levels and increased inflammatory markers in patients with cancer and relationship with cachexia.
Burney BO; Hayes TG; Smiechowska J; Cardwell G; Papusha V; Bhargava P; Konda B; Auchus RJ; Garcia JM
J Clin Endocrinol Metab; 2012 May; 97(5):E700-9. PubMed ID: 22419719
[TBL] [Abstract][Full Text] [Related]
6. [Leptin serum levels in cachectic and non-cachectic lung cancer patients].
Weryńska B; Kosacka M; Gołecki M; Jankowska R
Pneumonol Alergol Pol; 2009; 77(6):500-6. PubMed ID: 20013699
[TBL] [Abstract][Full Text] [Related]
7. Serum interleukin-15 levels in cancer patients with cachexia.
Martínez-Hernández PL; Hernanz-Macías Á; Gómez-Candela C; Grande-Aragón C; Feliu-Batlle J; Castro-Carpeño J; Martínez-Muñoz I; Zurita-Rosa L; Villarino-Sanz M; Prados-Sánchez C; Sánchez García-Girón J
Oncol Rep; 2012 Oct; 28(4):1443-52. PubMed ID: 22825570
[TBL] [Abstract][Full Text] [Related]
8. Peptide-2 from mouse myostatin precursor protein alleviates muscle wasting in cancer-associated cachexia.
Ojima C; Noguchi Y; Miyamoto T; Saito Y; Orihashi H; Yoshimatsu Y; Watabe T; Takayama K; Hayashi Y; Itoh F
Cancer Sci; 2020 Aug; 111(8):2954-2964. PubMed ID: 32519375
[TBL] [Abstract][Full Text] [Related]
9. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.
Benny Klimek ME; Aydogdu T; Link MJ; Pons M; Koniaris LG; Zimmers TA
Biochem Biophys Res Commun; 2010 Jan; 391(3):1548-54. PubMed ID: 20036643
[TBL] [Abstract][Full Text] [Related]
10. Energy deprivation alters in a leptin- and cortisol-independent manner circulating levels of activin A and follistatin but not myostatin in healthy males.
Vamvini MT; Aronis KN; Chamberland JP; Mantzoros CS
J Clin Endocrinol Metab; 2011 Nov; 96(11):3416-23. PubMed ID: 21865351
[TBL] [Abstract][Full Text] [Related]
11. Irisin mRNA and circulating levels in relation to other myokines in healthy and morbidly obese humans.
Vamvini MT; Aronis KN; Panagiotou G; Huh JY; Chamberland JP; Brinkoetter MT; Petrou M; Christophi CA; Kales SN; Christiani DC; Mantzoros CS
Eur J Endocrinol; 2013 Dec; 169(6):829-34. PubMed ID: 24062354
[TBL] [Abstract][Full Text] [Related]
12. Activin subfamily peptides predict chronological age in humans.
Barrios-Silva LV; Parnell M; Shinwari ZB; Chaudhary GA; Xenofontos T; van Bekhoven A; McArthur S; Elliott BT
Physiol Rep; 2018 Sep; 6(17):e13823. PubMed ID: 30178598
[TBL] [Abstract][Full Text] [Related]
13. Leptin treatment reduces body fat but does not affect lean body mass or the myostatin-follistatin-activin axis in lean hypoleptinemic women.
Brinkoetter M; Magkos F; Vamvini M; Mantzoros CS
Am J Physiol Endocrinol Metab; 2011 Jul; 301(1):E99-E104. PubMed ID: 21505147
[TBL] [Abstract][Full Text] [Related]
14. Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function.
Stephens NA; Gray C; MacDonald AJ; Tan BH; Gallagher IJ; Skipworth RJ; Ross JA; Fearon KC; Greig CA
Clin Nutr; 2012 Aug; 31(4):499-505. PubMed ID: 22296872
[TBL] [Abstract][Full Text] [Related]
15. Can the Serum Level of Myostatin be Considered as an Informative Factor for Cachexia Prevention in Patients with Medullary Thyroid Cancer?
Hedayati M; Nozhat Z; Hannani M
Asian Pac J Cancer Prev; 2016; 17(S3):119-23. PubMed ID: 27165248
[TBL] [Abstract][Full Text] [Related]
16. Myostatin serum concentration as an indicator for deviated muscle metabolism in severe burn injuries.
Wallner C; Wagner JM; Dittfeld S; Drysch M; Lehnhardt M; Behr B
Scand J Surg; 2019 Dec; 108(4):297-304. PubMed ID: 30474468
[TBL] [Abstract][Full Text] [Related]
17. Significance of serum Myostatin in hemodialysis patients.
Esposito P; Battaglia Y; La Porta E; Grignano MA; Caramella E; Avella A; Peressini S; Sessa N; Albertini R; Di Natali G; Lisi C; Gregorini M; Rampino T
BMC Nephrol; 2019 Dec; 20(1):462. PubMed ID: 31829144
[TBL] [Abstract][Full Text] [Related]
18. Increased plasma ghrelin level in lung cancer cachexia.
Shimizu Y; Nagaya N; Isobe T; Imazu M; Okumura H; Hosoda H; Kojima M; Kangawa K; Kohno N
Clin Cancer Res; 2003 Feb; 9(2):774-8. PubMed ID: 12576449
[TBL] [Abstract][Full Text] [Related]
19. Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin.
Gilson H; Schakman O; Kalista S; Lause P; Tsuchida K; Thissen JP
Am J Physiol Endocrinol Metab; 2009 Jul; 297(1):E157-64. PubMed ID: 19435857
[TBL] [Abstract][Full Text] [Related]
20. Cross-talk between the heart and adipose tissue in cachectic heart failure patients with respect to alterations in body composition: a prospective study.
Christensen HM; Kistorp C; Schou M; Keller N; Zerahn B; Frystyk J; Flyvbjerg A; Faber J
Metabolism; 2014 Jan; 63(1):141-9. PubMed ID: 24140097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
